Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1503 entries
Sorted by: Best Match Show Resources per page
Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy.

Korean journal of pediatrics

Yoon BG, Baek HJ, Oh BS, Han DK, Choi YD, Kook H.
PMID: 26770227
Korean J Pediatr. 2015 Dec;58(12):505-8. doi: 10.3345/kjp.2015.58.12.505. Epub 2015 Dec 22.

It is uncommon for pediatric patients with rhabdomyosarcoma to present with clinical and/or laboratory features of disseminated intravascular coagulation (DIC). We report a case of metastatic alveolar rhabdomyosarcoma with severe bleeding because of DIC in a 13-year-old boy. He...

Cite
Yoon BG, Baek HJ, Oh BS, et al. Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy. Korean J Pediatr. 2015;58(12):505-8doi: 10.3345/kjp.2015.58.12.505.
Yoon, B. G., Baek, H. J., Oh, B. S., Han, D. K., Choi, Y. D., & Kook, H. (2015). Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy. Korean journal of pediatrics, 58(12), 505-8. https://doi.org/10.3345/kjp.2015.58.12.505
Yoon, Byung Gyu, et al. "Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy." Korean journal of pediatrics vol. 58,12 (2015): 505-8. doi: https://doi.org/10.3345/kjp.2015.58.12.505
Yoon BG, Baek HJ, Oh BS, Han DK, Choi YD, Kook H. Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy. Korean J Pediatr. 2015 Dec;58(12):505-8. doi: 10.3345/kjp.2015.58.12.505. Epub 2015 Dec 22. PMID: 26770227; PMCID: PMC4705332.
Copy Download .nbib Format: NLM
Anti-cancer potential of flavonoids: recent trends and future perspectives.

3 Biotech

Batra P, Sharma AK.
PMID: 28324424
3 Biotech. 2013 Dec;3(6):439-459. doi: 10.1007/s13205-013-0117-5. Epub 2013 Feb 12.

Cancer is a major public health concern in both developed and developing countries. Several plant-derived anti-cancer agents including taxol, vinblastine, vincristine, the campothecin derivatives, topotecan, irinotecan and etoposide are in clinical use all over the world. Other promising anti-cancer...

Cite
Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech. 2013;3(6):439-459doi: 10.1007/s13205-013-0117-5.
Batra, P., & Sharma, A. K. (2013). Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech, 3(6), 439-459. https://doi.org/10.1007/s13205-013-0117-5
Batra, Priya, and Sharma, Anil K. "Anti-cancer potential of flavonoids: recent trends and future perspectives." 3 Biotech vol. 3,6 (2013): 439-459. doi: https://doi.org/10.1007/s13205-013-0117-5
Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech. 2013 Dec;3(6):439-459. doi: 10.1007/s13205-013-0117-5. Epub 2013 Feb 12. PMID: 28324424; PMCID: PMC3824783.
Copy Download .nbib Format: NLM
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag.

Case reports in hematology

Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ.
PMID: 26180646
Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 09.

Severe refractory ITP is clinically challenging and a variety of single or combination chemotherapies have been tried with limited outcome. We report a case of ITP that was unresponsive to multiple agents including high-dose steroid, IVIG, Rho(D) immune globulin,...

Cite
Anwer F, Yun S, Nair A, et al. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015;2015:583451doi: 10.1155/2015/583451.
Anwer, F., Yun, S., Nair, A., Ahmad, Y., Krishnadashan, R., & Deeg, H. J. (2015). Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case reports in hematology, 2015583451. https://doi.org/10.1155/2015/583451
Anwer, Faiz, et al. "Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag." Case reports in hematology vol. 2015 (2015): 583451. doi: https://doi.org/10.1155/2015/583451
Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 09. PMID: 26180646; PMCID: PMC4477130.
Copy Download .nbib Format: NLM
Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma.

Case reports in obstetrics and gynecology

Alturkistani H, Almarzooqi MK, Oliva V, Gilbert P.
PMID: 27403360
Case Rep Obstet Gynecol. 2016;2016:6353471. doi: 10.1155/2016/6353471. Epub 2016 Jun 14.

This is a case of choriocarcinoma that did not regress after chemotherapy treatment. A 30-year-old female patient (gravida 2, para 2), presented to our ER with stroke and persistent mild pelvic pain 2 months after a Caesarean section. Computed...

Cite
Alturkistani H, Almarzooqi MK, Oliva V, et al. Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma. Case Rep Obstet Gynecol. 2016;2016:6353471doi: 10.1155/2016/6353471.
Alturkistani, H., Almarzooqi, M. K., Oliva, V., & Gilbert, P. (2016). Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma. Case reports in obstetrics and gynecology, 20166353471. https://doi.org/10.1155/2016/6353471
Alturkistani, Husain, et al. "Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma." Case reports in obstetrics and gynecology vol. 2016 (2016): 6353471. doi: https://doi.org/10.1155/2016/6353471
Alturkistani H, Almarzooqi MK, Oliva V, Gilbert P. Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma. Case Rep Obstet Gynecol. 2016;2016:6353471. doi: 10.1155/2016/6353471. Epub 2016 Jun 14. PMID: 27403360; PMCID: PMC4923520.
Copy Download .nbib Format: NLM
Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.

Oncology letters

Komeno Y, Uchida N, Satoh Y, Uryu H, Iwata Y, Masuda A, Iihara K, Yatomi Y, Taniguchi S, Ryu T.
PMID: 28599428
Oncol Lett. 2017 Jun;13(6):4285-4289. doi: 10.3892/ol.2017.5989. Epub 2017 Apr 05.

A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase....

Cite
Komeno Y, Uchida N, Satoh Y, et al. Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncol Lett. 2017;13(6):4285-4289doi: 10.3892/ol.2017.5989.
Komeno, Y., Uchida, N., Satoh, Y., Uryu, H., Iwata, Y., Masuda, A., Iihara, K., Yatomi, Y., Taniguchi, S., & Ryu, T. (2017). Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncology letters, 13(6), 4285-4289. https://doi.org/10.3892/ol.2017.5989
Komeno, Yukiko, et al. "Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report." Oncology letters vol. 13,6 (2017): 4285-4289. doi: https://doi.org/10.3892/ol.2017.5989
Komeno Y, Uchida N, Satoh Y, Uryu H, Iwata Y, Masuda A, Iihara K, Yatomi Y, Taniguchi S, Ryu T. Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncol Lett. 2017 Jun;13(6):4285-4289. doi: 10.3892/ol.2017.5989. Epub 2017 Apr 05. PMID: 28599428; PMCID: PMC5452986.
Copy Download .nbib Format: NLM
A T-cell prolymphocytic leukemia case with central nervous system involvement.

International journal of clinical and experimental medicine

Malkan UY, Gunes G, Yayar O, Demiroglu H, Yesilirmak A, Uner A.
PMID: 26550397
Int J Clin Exp Med. 2015 Aug 15;8(8):14207-9. eCollection 2015.

T-cell prolymphocytic leukemia (T-PLL) is an aggressive mature T cell neoplasm that typically involves peripheral blood, bone marrow, lymph nodes and spleen. It is a rare disease that comprises 2-5% of mature lymphocytic leukemia in adults. Here we present...

Cite
Malkan UY, Gunes G, Yayar O, et al. A T-cell prolymphocytic leukemia case with central nervous system involvement. Int J Clin Exp Med. 2015;8(8):14207-9
Malkan, U. Y., Gunes, G., Yayar, O., Demiroglu, H., Yesilirmak, A., & Uner, A. (2015). A T-cell prolymphocytic leukemia case with central nervous system involvement. International journal of clinical and experimental medicine, 8(8), 14207-9.
Malkan, Umit Yavuz, et al. "A T-cell prolymphocytic leukemia case with central nervous system involvement." International journal of clinical and experimental medicine vol. 8,8 (2015): 14207-9.
Malkan UY, Gunes G, Yayar O, Demiroglu H, Yesilirmak A, Uner A. A T-cell prolymphocytic leukemia case with central nervous system involvement. Int J Clin Exp Med. 2015 Aug 15;8(8):14207-9. eCollection 2015. PMID: 26550397; PMCID: PMC4613082.
Copy Download .nbib Format: NLM
Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience.

Journal of Cancer

Hagmann R, Hess V, Zippelius A, Rothschild SI.
PMID: 26516363
J Cancer. 2015 Sep 15;6(11):1148-54. doi: 10.7150/jca.13080. eCollection 2015.

BACKGROUND: Randomized trials established topotecan and the combination of adriamycin, cyclophosphamide and vincristine (ACO) as second-line therapy options for small-cell lung cancer. We retrospectively evaluated the outcome of SCLC patients undergoing second-line chemotherapy.PATIENTS AND METHODS: 92 consecutive patients with...

Cite
Hagmann R, Hess V, Zippelius A, et al. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015;6(11):1148-54doi: 10.7150/jca.13080.
Hagmann, R., Hess, V., Zippelius, A., & Rothschild, S. I. (2015). Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. Journal of Cancer, 6(11), 1148-54. https://doi.org/10.7150/jca.13080
Hagmann, Raphael, et al. "Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience." Journal of Cancer vol. 6,11 (2015): 1148-54. doi: https://doi.org/10.7150/jca.13080
Hagmann R, Hess V, Zippelius A, Rothschild SI. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015 Sep 15;6(11):1148-54. doi: 10.7150/jca.13080. eCollection 2015. PMID: 26516363; PMCID: PMC4615351.
Copy Download .nbib Format: NLM
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Seminars in oncology

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.
PMID: 28140093
Semin Oncol. 2002 Feb;29(1):56-69. doi: 10.1053/sonc.2002.30143.

Advanced-stage mantle cell lymphoma (MCL) is a disease for which no curative treatment strategy exists. Results with standard combination chemotherapy, with or without an anthracycline, are disappointing, and new and better therapies are needed. High-dose therapy and autologous stem-cell...

Cite
Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002;29(1):56-69doi: 10.1053/sonc.2002.30143.
Mangel, J., Buckstein, R., Imrie, K., Spaner, D., Crump, M., Tompkins, K., Reis, M., Perez-Ordonez, B., Deodhare, S., Romans, R., Pennell, N., Robinson, J. B., Hewitt, K., Richardson, P., Lima, A., Pavlin, P., & Berinstein, N. L. (2002). Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Seminars in oncology, 29(1), 56-69. https://doi.org/10.1053/sonc.2002.30143
Mangel, Joy, et al. "Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma." Seminars in oncology vol. 29,1 (2002): 56-69. doi: https://doi.org/10.1053/sonc.2002.30143
Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002 Feb;29(1):56-69. doi: 10.1053/sonc.2002.30143. PMID: 28140093.
Copy Download .nbib Format: NLM
Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.

Case reports in oncological medicine

Jannin A, Hennart B, Adenis A, Chauffert B, Penel N.
PMID: 29098099
Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26.

Alveolar rhabdomyosarcoma (AR) in adult patients is an exceptional malignancy. Management of AR is based on (neo)adjuvant chemotherapy combining ifosfamide, vincristine, and actinomycin D and local curative-intent surgery/radiotherapy. In cases of relapsing AR, the combination of temozolomide/irinotecan is regarded...

Cite
Jannin A, Hennart B, Adenis A, et al. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case Rep Oncol Med. 2017;2017:2683478doi: 10.1155/2017/2683478.
Jannin, A., Hennart, B., Adenis, A., Chauffert, B., & Penel, N. (2017). Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case reports in oncological medicine, 20172683478. https://doi.org/10.1155/2017/2683478
Jannin, Arnaud, et al. "Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism." Case reports in oncological medicine vol. 2017 (2017): 2683478. doi: https://doi.org/10.1155/2017/2683478
Jannin A, Hennart B, Adenis A, Chauffert B, Penel N. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26. PMID: 29098099; PMCID: PMC5634569.
Copy Download .nbib Format: NLM
Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

Current oncology (Toronto, Ont.)

MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH.
PMID: 28050137
Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21.

With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and...

Cite
MacDonald D, Prica A, Assouline S, et al. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016;23(6):407-417doi: 10.3747/co.23.3405.
MacDonald, D., Prica, A., Assouline, S., Christofides, A., Lawrence, T., & Sehn, L. H. (2016). Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Current oncology (Toronto, Ont.), 23(6), 407-417. https://doi.org/10.3747/co.23.3405
MacDonald, D, et al. "Emerging therapies for the treatment of relapsed or refractory follicular lymphoma." Current oncology (Toronto, Ont.) vol. 23,6 (2016): 407-417. doi: https://doi.org/10.3747/co.23.3405
MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21. PMID: 28050137; PMCID: PMC5176374.
Copy Download .nbib Format: NLM
Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma.

Clinical nephrology. Case studies

Miyata KN, Siddiqi NA, Kiss LP, Harbord NB, Winchester JF.
PMID: 29043141
Clin Nephrol Case Stud. 2017 Feb 03;5:9-15. doi: 10.5414/CNCS109036. eCollection 2017.

Renal involvement in non-Hodgkin lymphoma, especially mantle cell lymphoma (MCL) is rare. A 77-year-old man presented with acute kidney injury (AKI), which rapidly progressed to dialysis dependence. Kidney biopsy revealed patchy B-cell lymphocytic aggregates in the interstitium, which were...

Cite
Miyata KN, Siddiqi NA, Kiss LP, et al. Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clin Nephrol Case Stud. 2017;5:9-15doi: 10.5414/CNCS109036.
Miyata, K. N., Siddiqi, N. A., Kiss, L. P., Harbord, N. B., & Winchester, J. F. (2017). Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clinical nephrology. Case studies, 59-15. https://doi.org/10.5414/CNCS109036
Miyata, Kana N, et al. "Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma." Clinical nephrology. Case studies vol. 5 (2017): 9-15. doi: https://doi.org/10.5414/CNCS109036
Miyata KN, Siddiqi NA, Kiss LP, Harbord NB, Winchester JF. Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clin Nephrol Case Stud. 2017 Feb 03;5:9-15. doi: 10.5414/CNCS109036. eCollection 2017. PMID: 29043141; PMCID: PMC5438003.
Copy Download .nbib Format: NLM
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ, Ferhanoğlu B, Soysal T, Başlar Z, Aydın Y.
PMID: 25541654
Turk J Haematol. 2014 Dec 05;31(4):374-80. doi: 10.4274/tjh.2013.0004.

OBJECTIVE: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels.MATERIALS AND METHODS: One hundred and thirteen patients with MM were included in the study. Patients...

Cite
Çetin G, Eşkazan AE, Ar MC, et al. Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol. 2014;31(4):374-80doi: 10.4274/tjh.2013.0004.
Çetin, G., Eşkazan, A. E., Ar, M. C., Aydın, �. �. �. �., Ferhanoğlu, B., Soysal, T., Başlar, Z., & Aydın, Y. (2014). Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish journal of haematology : official journal of Turkish Society of Haematology, 31(4), 374-80. https://doi.org/10.4274/tjh.2013.0004
Çetin, Güven, et al. "Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri." Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 31,4 (2014): 374-80. doi: https://doi.org/10.4274/tjh.2013.0004
Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ, Ferhanoğlu B, Soysal T, Başlar Z, Aydın Y. Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol. 2014 Dec 05;31(4):374-80. doi: 10.4274/tjh.2013.0004. PMID: 25541654; PMCID: PMC4454052.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1503 entries